A recent engadget article noted the first human Ebola vaccine to receive EU approval. Merck’s ERVEBO is the product of a unique collaboration between the Public Health Agency of Canada and the US Army over ten years ago. Merck acquired the rights to develop the vaccine after the 2014 Ebola outbreak in West Africa. On November 11th, the vaccine received a “conditional marketing authorization,” a distinction typically designated for medicines that treat unmet medical needs.
Quick Hits: EU Approves Human Ebola Vaccine
In a new first, Merck’s Ebola vaccine received a “conditional marketing authorization” from the European Union.
Nov 20, 2019
Fill out the form below to request more information about Quick Hits: EU Approves Human Ebola Vaccine
Recommended
Recommended
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
